Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: Role of A-Raf and C-Raf in serum-induced proliferation

Molecular Pharmacology

Volumn 51, Issue 3, 1997, Pages 383-389

  Cioffi, Catherine L ^a   Garay, Michelle ^a   Johnston, Joseph F ^b   McGraw, Kathy ^b   Boggs, Russell T ^b   Hreniuk, David ^a   Monia, Brett P ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ISIS 11061; ISIS 9069; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; INHIBITION KINETICS; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASCULARIZATION;

ANIMALS; CELL DIVISION; CELL LINE; GENE EXPRESSION REGULATION; ISOENZYMES; MOLECULAR SEQUENCE DATA; MUSCLE, SMOOTH, VASCULAR; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RAF; RATS; RNA, MESSENGER;

EID: 0030889954     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Morrison, D. K., D. R. Kaplan, U. Rapp, and T. M. Roberts. Signal transduction from membrane to cytoplasm: growth factors and membrane-bound oncogene products increase Raf-1 phosphorylation and associated protein kinase activity. Proc. Natl. Acad. Sci. USA 85:8855-8859 (1988).
2. Turner, B., U. Rapp, H. App, M. Greene, K. Dobashi, and J. Reed. Interleukin 2 induces tyrosine phosphorylation and activation of p72-74 Raf-1 kinase in a T-cell line. Proc. Natl. Acad. Sci. USA 88:1227-1231 (1991).
3. Leevers, S. J., H. F. Paterson, and C. J. Marshall. Requirement for ras in raf activation is overcome by targeting raf to the plasma membrane. Nature (Lond.) 369:411-414 (1994).
4. Stokoe, D., S. G. Macdonald, K. Cadwallader, M. Symons, and J. F. Hancock. Activation of Raf as a result of recruitment to the plasma membrane. Science (Washington D. C.) 264:1463-1466 (1994).
5. Kolch, W., G. Heidecker, G. Kochs, R. Hummel, H. Vahidi, H. Mischak, G. Finkenzeller, D. Marme, and U. R. Rapp. Protein kinase Cα activates RAF-1 by direct phosphorylation. Nature (Lond.) 364:249-252 (1993).
6. Marais, R., Y. Light, H. F. Paterson, and C. J. Marshall. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J. 14:3136-3145 (1995).
7. Davis, R. J. The mitogen-activated protein kinase signal transduction pathway. J. Biol. Chem. 268:14553-14556 (1993).
8. Daum, G., I. Eisenmann-Tappe, H.-W. Fries, J. Troppmair, and U. R. Rapp. The ins and outs of Raf kinases. Trends Biol. Sci. 19:474-480 (1994).
9. Avruch, J., X.-F. Zhang, and J. M. Kyriakis. Raf meets Ras: completing the framework of a signal transduction pathway. Trends Biol. Sci. 19:279-283 (1994).
10. Storm, S. M., J. L. Cleveland, and U. R. Rapp. Expression of raf family proto-oncogenes in normal mouse tissues. Oncogene 5:345-351 (1990).
11. Troppmair, J., J. T. Bruder, H. Munoz, P. A. Lloyd, J. Kyriakis, P. Banerjee, J. Avruch, and U. R. Rapp. Mitogen-activated protein kinase/extracellular signal-regulated protein kinase activation by oncogenes, serum, and 12-O-tetradecanoylphorbol-13-acetate requires raf and is necessary for transformation. J. Biol. Chem. 269:7030-7035 (1994).
12. Kizaka-Kondoh, S., K. Sato, K. Tamura, H. Nojima, and H. Okayama. Raf-1 protein kinase is an integral component of the oncogenic signal cascade shared by epidermal growth factor and platelet-derived growth factor. Mol. Cell. Biol. 12:5078-5086 (1992).
13. Miltenberger, R. J., J. Cortnet, and P. J. Farnham. An inhibitory raf-1 mutant suppresses expression of a subset of v-raf-activated genes. J. Biol. Chem. 268:15674-15680 (1993).
14. Kolch, W., G. Heidecker, P. Lloyd, and U. R. Rapp. Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature (Lond.) 349:426-428 (1991).
15. Monia, B. P., J. F. Johnston, T. Geiger, M. Muller, and D. Fabbro. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med. 2:668-675 (1996).
16. Vaillancourt, R. R., A. M. Gardner, and G. L. Johnson. B-Raf-dependent regulation of the MEK-1/mitogen-activated protein kinase pathway in PC12 cells and regulation by cyclic AMP. Mol. Cell. Biol. 14:6522-6530 (1994).
17. Bogoyevitch, M. A., C. J. Marshall, and P. H. Sugden. Hypertrophic agonists stimulate the activities of the protein kinases c-Raf and A-Raf in cultured ventricular myocytes. J. Biol. Chem. 270:26303-26310 (1995).
18. Reuter, C. W. M., A. D. Catling, T. Jelinek, and M. J. Weber. Biochemical analysis of MEK activation in NIH3T3 fibroblasts. Identification of B-Raf and other activators. J. Biol. Chem. 270:7644-7655 (1995).
19. Wu, X., S. J. Noh, G. Zhou, J. E. Dixon, and K.-L. Guan. Selective activation of MEK1 but not MEK2 by A-Raf from epidermal growth factor-stimulated Hela cells. J. Biol. Chem. 271:3265-3271 (1996).
20. Schlessinger, J. SH2/SH3 signaling proteins. Curr. Opin. Genet. Develop. 4:25-30 (1994).
21. Shi, Y., H. G. Hutchinson, D. J. Hall, and A. Zalewski. Downregulation of c-myc expression by antisense oligonucleotides inhibits proliferation of human smooth muscle cells. Circulation 88:1190-1195 (1993).
22. Speir, E., and S. E. Epstein. Inhibition of smooth muscle cell proliferation by an antisense oligodeoxynucleotide targeting the messenger RNA encoding proliferating cell nuclear antigen. Circulation 86:538-547 (1992).
23. Chaikof, E. L., R. Caban, C.-N. Yan, G. N. Rao, and M. S. Runge. Growth-related responses in arterial smooth muscle cells are arrested by thrombin receptor antisense sequences. J. Biol. Chem. 270:7431-7436 (1995).
24. Delafontaine, P., X. P. Meng, L. Ku, and J. Du. Regulation of vascular smooth muscle cell insulin-like growth factor 1 receptors by phosphorothioate oligonucleotides. Effects on cell growth and evidence that sense targeting at the ATG site increases receptor expression. J. Biol. Chem. 270:14383-14388 (1995).
25. Simons, M., E. R. Edelman, and R. D. Rosenberg. Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimai hyperplasia in a rat carotid artery injury model. J. Clin. Invest. 93:2351-2356 (1994).
26. Edelman, E. R., M. Simons, M. G. Sirois, and R. D. Rosenberg. c-myc in vasculoproliferative disease. Circ. Res. 76:176-182 (1995).
27. Monia, B. P., E. A. Lesnik, C. Gonzalez, W. F. Lima, D. McGee, C. J. Guinesse, A. M. Kawasaki, P. D. Cook, and S. M. Freier. Evaluation of 2′ modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268:14514-14522 (1993).
28. Puglisi, J. D., and I. Tinoco. Absorbance melting curves of RNA. Methods Enzymol. 180:304-325 (1989).
29. Petersheim, M., and D. H. Turner. Base-stacking and base pairing contributions to helix stability: thermodynamics of double-helix formation with CCGG, CCGGp, CCGGAp, ACCGGp, CCGGUp, and ACCGGUp. Biochemistry 22:256-263 (1983).
30. Dean, N. M., and R. McKay. Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci USA 91:11762-11766 (1994).
31. Bennett, C. F., M.-Y. Chiang, H. Chan, J. E. E. Shoemaker, and C. K. Mirabelli. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41:1023-1033 (1992).
32. Stein, C. A. Anti-sense oligodeoxynucleotides - promises and pitfalls. Leukemia 6:967-974 (1992).
33. Stein, C. A. Does antisense exist? It may, but only under very special circumstances. Nature Med. 1:1119-1121 (1995).
34. Wagner, R. W. Gene inhibition using antisense oligodeoxynucleotides. Nature (Lond.) 372:333-335, 1994.
35. Inoue, H., Y. Hayase, S. Iwai, and E. Ohtsuka. Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H. FEBS Lett. 215:327-330 (1987).
36. Vojtek, A. B., S. M. Hollenbuerg, and J. A. Cooper. Mammalian ras interacts directly with the serine/threonine kinase raf. Cell 74:205-214 (1993).
37. Okada, T., T. Masuda, M. Shinkai, K. Kariya, and T. Kataoka. Posttranslational modification of H-Ras is required for activation of, but not for association with, B-Raf. J. Biol. Chem. 271:4671-4678 (1996).
38. Irani, K., S. Herzlinger, and T. Finkel. Ras proteins regulate multiple mitogenic pathways in A10 vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 202:1252-1258 (1994).
39. Indolfi, C., E. V. Avvedimento, A. Rapacciuolo, E. Di Lornzo, G. Esposito, E. Stabile, A. Feliciello, E. Mele, P. Giuliano, G. Condorelli, and M. Chiariello. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nature Med. 1:541-545 (1995).
40. Shi, Y., A. Fard, A. Galeo, H. G. Hutchinson, P. Vermani, G. R. Dodge, D. J. Hall, F. Shaheen, and A. Zalewski. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation 90:944-951 (1994).